Beta-blockers for hemangiomas

Research output: Contribution to journalArticle

Abstract

Infantile hemangiomas (IHs) are the most common tumors in infancy. Their typical natural history is characterized by an early rapid growth in the first months of life and by a slow spontaneous involution in the first years of life. Even though spontaneous regression of IHs could suggest therapeutic abstention, systemic treatment is the therapy of choice in many patients in which these situations occur: 1) rapid growth of IHs; 2) location of IHs in aesthetically critic areas; 3) recurrent hemorrhages, ulcerations or infections of IHs; 3) IHs interfering with important physiological functions (breathing, feeding, vision, hearing, etc.); 4) large or multicentric IHs that can cause heart failure. Since 2008, systemic administration of propranolol, an old non-selective β-blocker, was found, serendipitously, to improve the treatment of IHs replacing older and more dangerous therapies like oral steroids, vincristine, interferon-alpha or vascular lasers. At present, oral propranolol has dramatically changed the approach of IHs because its efficacy is almost 100% and its action is rapid, without important side effects. The formal approval by FDA and EMA has been obtained in Spring 2014.

Original languageEnglish
Pages (from-to)703-709
Number of pages7
JournalGiornale Italiano di Dermatologia e Venereologia
Volume149
Issue number6
Publication statusPublished - Dec 1 2014

Fingerprint

Hemangioma
Propranolol
Therapeutics
Vincristine
Growth
Natural History
Interferon-alpha
Hearing
Blood Vessels
Respiration
Lasers
Heart Failure
Steroids
Hemorrhage
Infection

Keywords

  • Adrenergic beta-antagonists
  • Hemangioma
  • Propranolol
  • Steroids

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Beta-blockers for hemangiomas. / Gelmetti, C.; Cavalli, R.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 149, No. 6, 01.12.2014, p. 703-709.

Research output: Contribution to journalArticle

@article{51c87801e3394c58bd97dc431f2588f7,
title = "Beta-blockers for hemangiomas",
abstract = "Infantile hemangiomas (IHs) are the most common tumors in infancy. Their typical natural history is characterized by an early rapid growth in the first months of life and by a slow spontaneous involution in the first years of life. Even though spontaneous regression of IHs could suggest therapeutic abstention, systemic treatment is the therapy of choice in many patients in which these situations occur: 1) rapid growth of IHs; 2) location of IHs in aesthetically critic areas; 3) recurrent hemorrhages, ulcerations or infections of IHs; 3) IHs interfering with important physiological functions (breathing, feeding, vision, hearing, etc.); 4) large or multicentric IHs that can cause heart failure. Since 2008, systemic administration of propranolol, an old non-selective β-blocker, was found, serendipitously, to improve the treatment of IHs replacing older and more dangerous therapies like oral steroids, vincristine, interferon-alpha or vascular lasers. At present, oral propranolol has dramatically changed the approach of IHs because its efficacy is almost 100{\%} and its action is rapid, without important side effects. The formal approval by FDA and EMA has been obtained in Spring 2014.",
keywords = "Adrenergic beta-antagonists, Hemangioma, Propranolol, Steroids",
author = "C. Gelmetti and R. Cavalli",
year = "2014",
month = "12",
day = "1",
language = "English",
volume = "149",
pages = "703--709",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - Beta-blockers for hemangiomas

AU - Gelmetti, C.

AU - Cavalli, R.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Infantile hemangiomas (IHs) are the most common tumors in infancy. Their typical natural history is characterized by an early rapid growth in the first months of life and by a slow spontaneous involution in the first years of life. Even though spontaneous regression of IHs could suggest therapeutic abstention, systemic treatment is the therapy of choice in many patients in which these situations occur: 1) rapid growth of IHs; 2) location of IHs in aesthetically critic areas; 3) recurrent hemorrhages, ulcerations or infections of IHs; 3) IHs interfering with important physiological functions (breathing, feeding, vision, hearing, etc.); 4) large or multicentric IHs that can cause heart failure. Since 2008, systemic administration of propranolol, an old non-selective β-blocker, was found, serendipitously, to improve the treatment of IHs replacing older and more dangerous therapies like oral steroids, vincristine, interferon-alpha or vascular lasers. At present, oral propranolol has dramatically changed the approach of IHs because its efficacy is almost 100% and its action is rapid, without important side effects. The formal approval by FDA and EMA has been obtained in Spring 2014.

AB - Infantile hemangiomas (IHs) are the most common tumors in infancy. Their typical natural history is characterized by an early rapid growth in the first months of life and by a slow spontaneous involution in the first years of life. Even though spontaneous regression of IHs could suggest therapeutic abstention, systemic treatment is the therapy of choice in many patients in which these situations occur: 1) rapid growth of IHs; 2) location of IHs in aesthetically critic areas; 3) recurrent hemorrhages, ulcerations or infections of IHs; 3) IHs interfering with important physiological functions (breathing, feeding, vision, hearing, etc.); 4) large or multicentric IHs that can cause heart failure. Since 2008, systemic administration of propranolol, an old non-selective β-blocker, was found, serendipitously, to improve the treatment of IHs replacing older and more dangerous therapies like oral steroids, vincristine, interferon-alpha or vascular lasers. At present, oral propranolol has dramatically changed the approach of IHs because its efficacy is almost 100% and its action is rapid, without important side effects. The formal approval by FDA and EMA has been obtained in Spring 2014.

KW - Adrenergic beta-antagonists

KW - Hemangioma

KW - Propranolol

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=84928017999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928017999&partnerID=8YFLogxK

M3 - Article

C2 - 25366892

AN - SCOPUS:84928017999

VL - 149

SP - 703

EP - 709

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 6

ER -